CD200 Flow Cytometric Assessment and Semiquantitative Immunohistochemical Staining Distinguishes Hairy Cell Leukemia From Hairy Cell Leukemia-Variant and Other B-Cell Lymphoproliferative Disorders

Pillai, Vinodh; Pozdnyakova, Olga; Charest, Karry; Li, Betty; Shahsafaei, Aliakbar; Dorfman, David M.

doi:10.1309/ajcpebk31vqqnddr

Cited by 48 publications

(35 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Differential diagnosis Consider hairy cell leukemia; hairy cell leukemia variant; splenic marginal zone lymphoma; splenic diffuse red pulp small B-cell lymphoma (outlines for specific immunophenotypic profiles of differential entities [33][34][35][36] ).…”

Section: Determination Of Mrd After Therapymentioning

confidence: 99%

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

Grever

Abdel‐Wahab

Andritsos

et al. 2017

Blood

209

290

View full text Add to dashboard Cite

Hairy cell leukemia is an uncommon hematologic malignancy characterized by pancytopenia and marked susceptibility to infection. Tremendous progress in the management of patients with this disease has resulted in high response rates and improved survival, yet relapse and an appropriate approach to re-treatment present continuing areas for research. The disease and its effective treatment are associated with immunosuppression. Because more patients are being treated with alternative programs, comparison of results will require general agreement on definitions of response, relapse, and methods of determining minimal residual disease. The development of internationally accepted, reproducible criteria is of paramount importance in evaluating and comparing clinical trials to provide optimal care. Despite the success achieved in managing these patients, continued participation in available clinical trials in the first-line and particularly in the relapse setting is highly recommended. The Hairy Cell Leukemia Foundation convened an international conference to provide common definitions and structure to guide current management. There is substantial opportunity for continued research in this disease. In addition to the importance of optimizing the prevention and management of the serious risk of infection, organized evaluations of minimal residual disease and treatment at relapse offer ample opportunities for clinical research. Finally, a scholarly evaluation of quality of life in the increasing number of survivors of this now manageable chronic illness merits further study. The development of consensus guidelines for this disease offers a framework for continued enhancement of the outcome for patients

show abstract

Section: Determination Of Mrd After Therapymentioning

confidence: 99%

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

Grever

Abdel‐Wahab

Andritsos

et al. 2017

Blood

209

290

View full text Add to dashboard Cite

show abstract

“…A score of 3–4 was obtained in more than 98 % of patients with HCL, and a score of 0–2 was obtained in patients with HCLv and splenic lymphoma with villous lymphocytes. Recently, expression of CD200 and CD1d was shown to be consistent in HCL, which is useful for differential diagnosis [58, 57]. Table 2 provides a brief summary of the main differentials of classic HCL [81].…”

Section: Diagnosismentioning

confidence: 99%

“…HCL cells also overexpress CD11c, CD103, CD200, CD1d, cyclin D1, and annexin A1, which are essential in diagnosing HCL, although the functional significance of these molecules in the biology of HCL is unclear [57, 58, 36, 59]. Interestingly, HCL cells also overexpress cyclin D1 in the absence of translocation t(11;14), which is typically associated with mantle cell lymphoma [60].…”

Section: Introductionmentioning

confidence: 99%

Update on the Biology and Treatment Options for Hairy Cell Leukemia

Jain

Pemmaraju

Ravandi

2014

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

“…Из этого следует, что диагностическая панель нуж-дается в усовершенствовании. Одним из маркеров, рекомендуемых для включения в диагностическую панель многими авторами, является CD200 [6][7][8][9][10][11][12][13][14][15].…”

Section: Introductionunclassified

“…Отмечается высокая экс-прессия CD200 при ХЛЛ и типичном ВКЛ [6][7][8][9][10][11][12][13][14][15]. Вместе с тем в случае вариантного ВКЛ экспрессия СD200 низкая [13].…”

Section: Introductionunclassified

Role of Superficial CD200 Marker in Differential Diagnosis of Malignant B-Cell Lymphoproliferative Diseases

Mirolyubova¹,

Stadnik²,

Nikulina³

et al. 2017

Клиническая онкогематология

View full text Add to dashboard Cite

Background & Aims. Flow cytometry is successfully used for diagnosis of malignant lymphoproliferative disorders. However, there are atypical cases that are difficult to interpret; thus, new markers relevant for the differential diagnosis are to be searched for. The aim is to analyze CD200 expression in patients with B-cell lymphoproliferative disorders. Materials & Methods. 187 patients with chronic lymphocytic leukemia (CLL), 14 patients with mantle cell lymphoma (MCL), 9 patients with marginal zone lymphoma (MZL), and 5 patients with hairy cell leukemia (HCL) were enrolled in the study. Neoplasm was not confirmed in 12 subjects. The patients underwent the following tests: CBC, immunophenotyping of peripheral blood or bone marrow lymphocytes, and a cytogenetic test. In some cases, an additional immunohistochemical test of bone marrow trepanobiopsy or lymph node biopsy samples was required. Results. In all cases of CLL and HCL, the CD200 expression was positive; mean fluorescence intensity was higher in these cases as compared to other groups. Negative expression of CD200 prevailed in MCL patients; however, at the same time 2 cases of intermediate and positive expression were reported, both showing moderate fluorescence intensity values. CD200 expression was heterogeneous in MZL patients. Conclusion. The CD200 negative expression excludes typical HCL and CLL. Additional cytogenetic and immunnohistoсhemical tests should be performed in such cases to verify the diagnosis, first of all, MCL or MZL.

show abstract

CD200 Flow Cytometric Assessment and Semiquantitative Immunohistochemical Staining Distinguishes Hairy Cell Leukemia From Hairy Cell Leukemia-Variant and Other B-Cell Lymphoproliferative Disorders

Abstract: Assessment of the CD200 expression level is helpful to distinguish HCL from HCL-V and other B-cell lymphoproliferative disorders and in the differential diagnosis of B-cell neoplasms in general.

Cited by 48 publications

References 23 publications

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

Update on the Biology and Treatment Options for Hairy Cell Leukemia

Role of Superficial CD200 Marker in Differential Diagnosis of Malignant B-Cell Lymphoproliferative Diseases

Contact Info

Product

Resources

About